Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
Trial ID or NCT#
The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.
A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects
- - Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity. - Males and females of childbearing potential must agree to utilize effective contraception methods. - Ability to understand and sign a written informed consent form.
- - Females who are pregnant or breastfeeding. - Participation in any other clinical trial without prior approval from the Sponsor. - Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study. - Subjects receiving ongoing therapy with contraindicated drugs.
Contact us to find out if this trial is right for you.